Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NeoGenomics Laboratories (NEO)

NeoGenomics Q3 revenue rises 11% to $209 million; full-year guidance raised

Positive Impact 4 of 5 earnings

NeoGenomics reported third-quarter 2026 revenue of $209 million, up 11% from a year earlier, and a GAAP net loss of $8 million, down from $27 million. The company raised its full-year 2026 revenue and adjusted EBITDA guidance and narrowed its net loss outlook, and it said CEO Tony Zook will move to Executive Chairman as Warren Stone becomes CEO on January 4, 2027.

Key points

  • Q3 2026 revenue was $209 million, up 11%; clinical revenue was $195 million, up 13%, with NGS revenue up 29%.
  • Q3 2026 GAAP net loss was $8 million, compared with $27 million in Q3 2025; adjusted EBITDA was $19 million, up 53%.
  • Updated FY 2026 revenue guidance is $807 million to $809 million, up from $802 million to $806 million; adjusted EBITDA guidance is approximately $60 million, up from $56 million to $58 million.
  • Warren Stone, currently President and COO, will become CEO and a Board member effective January 4, 2027.

The filing

CompanyNeoGenomics Laboratories (NEO)
Form8-K, current report
Filed with the SECOct 28, 2026, 4:06 PM ET
Accession number0001077183-26-000078

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.